A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.

Sponsor
Qianfoshan Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05570071
Collaborator
(none)
90
2
29.3

Study Details

Study Description

Brief Summary

To investigate the immediate, short-term and long-term efficacy of vaginal radiofrequency therapy in the treatment of stress urinary incontinence, and to compare the efficacy of pelvic floor electromyography combined with biofeedback therapy in stress urinary incontinence.

Condition or Disease Intervention/Treatment Phase
  • Device: physical therapy
N/A

Detailed Description

Before treatment, patients with mild and moderate stress urinary incontinence were diagnosed according to the diagnostic criteria through medical history inquiry and gynecological physical examination, and patients were screened according to the inclusion and exclusion criteria. After informing two treatment plans and signing the informed consent, they were randomly divided into vaginal radiofrequency therapy group and electrical stimulation combined biofeedback group. After being included in the test, one hour urine pad test was conducted, and IIQ-7, PISQ-12 and FSFI questionnaires were completed. IIQ-7, PISQ-12 and FSFI questionnaires were followed up 1, 3, 6 and 12 months after treatment. After 3 months and 1 year of treatment, 1 hour urine pad test was given again.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Randomized Controlled Clinical Study of the Use of Vaginal Radiofrequency Therapy in Treatment of Stress Urinary Incontinence.
Anticipated Study Start Date :
Oct 20, 2022
Anticipated Primary Completion Date :
Mar 31, 2025
Anticipated Study Completion Date :
Mar 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: vaginal radiofrequency

vaginal radiofrequency therapy 4 times

Device: physical therapy
medical treatment of pelvic floor

Active Comparator: electromyography biofeedback

electromyography combined with biofeedback therapy 15 times

Device: physical therapy
medical treatment of pelvic floor

Outcome Measures

Primary Outcome Measures

  1. Urine leakage in 1-hour pad test [before therapy]

    measure the urine leakage in 1-hour pad test

  2. Change from urine leakage at 3 months [3months after therapy]

    measure the urine leakage in 1-hour pad test at 3 months

  3. Change from urine leakage at 12 months [12months after therapy]

    measure the urine leakage in 1-hour pad test at 12 months

Secondary Outcome Measures

  1. incontinence impact questionnaire short form,IIQ-7 [before therapy]

    Urinary incontinence may affect daily activities, interpersonal relationships or personal emotions.The minimum value is 0,and the maximum value is 21. Higher scores mean a worse outcome.

  2. incontinence impact questionnaire short form,IIQ-7 [3months after therapy]

    Urinary incontinence may affect daily activities, interpersonal relationships or personal emotions.The minimum value is 0,and the maximum value is 21. Higher scores mean a worse outcome.

  3. incontinence impact questionnaire short form,IIQ-7 [12months after therapy]

    Urinary incontinence may affect daily activities, interpersonal relationships or personal emotions.The minimum value is 0,and the maximum value is 21. Higher scores mean a worse outcome.

  4. pelvic organ prolapsed-incontinence sexual questionnaire, PISQ-12 [before therapy]

    The sexual desire,orgasm,pain,urine leakage in sex of the participants.The minimum value is 0,and the maximum value is 48.Higher scores mean a better outcome.

  5. pelvic organ prolapsed-incontinence sexual questionnaire, PISQ-12 [3months after therapy]

    The sexual desire,orgasm,pain,urine leakage in sex of the participants.The minimum value is 0,and the maximum value is 48.Higher scores mean a better outcome.

  6. pelvic organ prolapsed-incontinence sexual questionnaire, PISQ-12 [12months after therapy]

    The sexual desire,orgasm,pain,urine leakage in sex of the participants.The minimum value is 0,and the maximum value is 48.Higher scores mean a better outcome.

  7. Female Sexual index,FSFI [before therapy]

    Sex frequency,sexual satisfaction, physiological factors, affective factor , sexual partner factor. The minimum value is 0,and the maximum value is 124.Higher scores mean a better outcome.

  8. Female Sexual index,FSFI [3months after therapy]

    Sex frequency,sexual satisfaction, physiological factors, affective factor , sexual partner factor. The minimum value is 0,and the maximum value is 124.Higher scores mean a better outcome.

  9. Female Sexual index,FSFI [12months after therapy]

    Sex frequency,sexual satisfaction, physiological factors, affective factor , sexual partner factor.The minimum value is 0,and the maximum value is 124. Higher scores mean a better outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:

18-75 years old women with a sexual history, and patients with mild to moderate stress urinary incontinence.

Exclusion Criteria:

Severe cardiopulmonary insufficiency, acute pelvic inflammatory disease or other infectious stage, non-steroidal anti-inflammatory drugs and steroid hormones affecting collagen production factors, POP-Q-2 and above prolapse.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Qianfoshan Hospital

Investigators

  • Study Director: Li Yan, The First Affiliated Hospital of Shandong First Medical University
  • Principal Investigator: Miao Yuan, The First Affiliated Hospital of Shandong First Medical University
  • Principal Investigator: Fangfang Zhao, The First Affiliated Hospital of Shandong First Medical University
  • Principal Investigator: Guangli Liu, The First Affiliated Hospital of Shandong First Medical University
  • Principal Investigator: Jing Li, The First Affiliated Hospital of Shandong First Medical University
  • Principal Investigator: Min Lu, The First Affiliated Hospital of Shandong First Medical University
  • Principal Investigator: Hongyan Niu, The First Affiliated Hospital of Shandong First Medical University
  • Principal Investigator: Dongyue Wang, The First Affiliated Hospital of Shandong First Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Li Yan, pfofessor, Qianfoshan Hospital
ClinicalTrials.gov Identifier:
NCT05570071
Other Study ID Numbers:
  • 2022001
First Posted:
Oct 6, 2022
Last Update Posted:
Oct 12, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2022